Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study
The randomized, controlled PALISADE trial demonstrated the benefit of daily oral immunotherapy with Peanut (Arachis Hypogaea) allergen powder-dnfp (PTAH, formerly AR101) in peanut-allergic children and adolescents.ARC004, the open-label follow-on study to PALISADE, used 5 dosing cohorts to explore P...
Bewaard in:
Gelijkaardige items
-
Eliciting Dose and Safety Outcomes From a Large Dataset of Standardized Multiple Food Challenges
door: Purington, Natasha, et al.
Gepubliceerd in: (2018) -
Comparison of sublingual immunotherapy and oral immunotherapy in peanut allergy
door: Zhang, Wenming, et al.
Gepubliceerd in: (2018) -
Eliciting Dose and Safety Outcomes From a Large Dataset of Standardized Multiple Food Challenges
door: Natasha Purington, et al.
Gepubliceerd in: (2018) -
New Treatment Directions in Food Allergy
door: Sampath, Vanitha, et al.
Gepubliceerd in: (2018) -
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results
door: Jacqueline A. Pongracic, et al.
Gepubliceerd in: (2021)